英文药名: Cytoxan(Cyclophosphamide Tablets and Injections) 中文药名: 环磷酰胺注射剂 药品说明； 【化学名称】对-［双-(β-氯乙基)胺基］-β-苯丙氨酸。 【别名】癌得星、安道生、CTX。 【药理及作用】本品属细胞毒类药物，主要是通过杀伤免疫细胞，阻止其增殖而抑制免疫反应。主要用于经常复发的肾病综合征和激素依赖型肾病综合征。与激素同用，有可能减少激素的副作用。 本品在体外无活性，进入体内被肝脏或肿瘤内存在的过量的磷酰胺酶或磷酸酶水解，变为活化作用型的磷酰胺氮芥而起作用。其作用机制与氮芥相似，与DNA发生交叉联结，抑制DNA的合成，也可干扰RNA的功能，属细胞周期非特异性药物。本品抗瘤谱广，对多种肿瘤有抑制作用。 【药代动力学】环磷酰胺口服易吸收，迅速分布全身，约1小时后达血浆峰浓度，在肝脏转化释出磷酰胺氮芥，其代谢产物约50%与蛋白结合。静注后血浆半衰期4～6小时，48小时内经肾脏排出50%～70%，其中68%为代谢产物，32%为原形。 【适应症】本品为目前广泛应用的抗癌药物，对恶性淋巴瘤、急性或慢性淋巴细胞白血病、多发性骨髓瘤有较好的疗效，对乳腺癌、睾丸肿瘤、卵巢癌、肺癌、头颈部鳞癌、鼻咽癌、神经母细胞瘤、横纹肌肉瘤及骨肉瘤均有一定的疗效。 【用法】每天每千克体重2-3毫克，可分为两次口服。亦可将两天的剂量加入注射用生理盐水内，隔日静脉注射1次。累积量不超过每千克体重150毫克。 【不良反应】骨髓抑制：白细胞减少较血小板减少为常见，最低值在用药后1～2周，多在2～3周后恢复。对肝功有影响。胃肠道反应：包括食欲减退、恶心及呕吐，一般停药1～3天即可消失。泌尿道反应：当大剂量环磷酰胺静滴，而缺乏有效预防措施时，可致出血性膀胱炎，表现为膀胱刺激症状、少尿、血尿及蛋白尿，系其代谢产物丙烯醛刺激膀胱所致，但环磷酰胺常规剂量应用时，其发生率较低。其他反应尚包括脱发、口腔炎、中毒性肝炎、皮肤色素沉着、月经紊乱、无精子或精子减少及肺纤维化等。 【禁忌】抗癌药物，必须在有经验的专科医生指导下用药。凡有骨髓抑制、感染、肝肾功能损害者禁用或慎用。对本品过敏者禁用。妊娠及哺乳期妇女禁用。 【注意】 1.本品早期副作用有骨髓抑制（白细胞减少等），感染，出血性膀胱炎，脱发，胃肠道反应；远期副作用有生殖系统功能损害（主要为睾丸生精能力损害，停经及卵巢纤维化较少见），发生恶性肿瘤。 2.用药期间，特别是用药后1-2周，定期检查血白细胞，如白细胞≤3Χ109/升，应减少本药的剂量或暂停使用。以免其代谢产物停留在膀胱内时间过长，而引起出血性膀胱炎。 【孕妇及哺乳期妇女用药】有致突变、致畸胎作用，可造成胎儿死亡或先天畸形，妊娠妇女禁用。本品可在乳汁中排出，在开始用药时必须中止哺乳。 【药物相互作用】环磷酰胺可使血清中假胆碱酯酶减少，使血清尿酸水平增高，因此，与抗痛风药如别嘌呤醇、秋水仙碱、丙磺舒等同用时，应调整抗痛风药物的剂量。此外也加强了琥珀胆碱的神经肌肉阻滞作用，可使呼吸暂停延长。环磷酰胺可抑制胆碱酯酶活性，因而延长可卡因的作用并增加毒性。大剂量巴比妥类、皮质激素类药物可影响环磷酰胺的代谢，同时应用可增加环磷酰胺的急性毒性。 【贮藏】遮光，密闭，在30℃以下保存。 Cytoxan Generic Name: cyclophosphamide Dosage Form: injection, powder, for solution; tablets Cytoxan® (cyclophosphamide for injection, USP) Cytoxan® Tablets (cyclophosphamide tablets, USP) Cytoxan Description Cytoxan® (cyclophosphamide for injection, USP) is a sterile white powder containing cyclophosphamide monohydrate. Cytoxan Tablets (cyclophosphamide tablets, USP) are for oral use and contain 25 mg or 50 mg cyclophosphamide (anhydrous). Inactive ingredients in Cytoxan Tablets are: acacia, FD&C Blue No. 1, D&C Yellow No. 10 Aluminum Lake, lactose, magnesium stearate, starch, stearic acid and talc. Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. Cyclophosphamide is a white crystalline powder with the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1. The chemical name for cyclophosphamide is 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate. Cyclophosphamide is soluble in water, saline, or ethanol and has the following structural formula: Cytoxan - Clinical Pharmacology Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites by a mixed function microsomal oxidase system. These metabolites interfere with the growth of susceptible rapidly proliferating malignant cells. The mechanism of action is thought to involve cross-linking of tumor cell DNA. Cyclophosphamide is well absorbed after oral administration with a bioavailability greater than 75%. The unchanged drug has an elimination half-life of 3 to 12 hours. It is eliminated primarily in the form of metabolites, but from 5 to 25% of the dose is excreted in urine as unchanged drug. Several cytotoxic and noncytotoxic metabolites have been identified in urine and in plasma. Concentrations of metabolites reach a maximum in plasma 2 to 3 hours after an intravenous dose. Plasma protein binding of unchanged drug is low but some metabolites are bound to an extent greater than 60%. It has not been demonstrated that any single metabolite is responsible for either the therapeutic or toxic effects of cyclophosphamide. Although elevated levels of metabolites of cyclophosphamide have been observed in patients with renal failure, increased clinical toxicity in such patients has not been demonstrated. Indications and Usage for Cytoxan Malignant Diseases Cytoxan, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to Cytoxan treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (Cytoxan given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. Nonmalignant Disease Biopsy Proven “Minimal Change” Nephrotic Syndrome in Children Cytoxan is useful in carefully selected cases of biopsy proven “minimal change” nephrotic syndrome in children but should not be used as primary therapy. In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, Cytoxan may induce a remission. Cytoxan is not indicated for the nephrotic syndrome in adults or for any other renal disease. Contraindications Continued use of cyclophosphamide is contraindicated in patients with severely depressed bone marrow function. Cyclophosphamide is contraindicated in patients who have demonstrated a previous hypersensitivity to it. See WARNINGS and PRECAUTIONS. Warnings Carcinogenesis, Mutagenesis, and Impairment of Fertility Second malignancies have developed in some patients treated with cyclophosphamide used alone or in association with other antineoplastic drugs and/or modalities. Most frequently, they have been urinary bladder, myeloproliferative, or lymphoproliferative malignancies. Second malignancies most frequently were detected in patients treated for primary myeloproliferative or lymphoproliferative malignancies or nonmalignant disease in which immune processes are believed to be involved pathologically. In some cases, the second malignancy developed several years after cyclophosphamide treatment had been discontinued. In a single breast cancer trial utilizing two to four times the standard dose of cyclophosphamide in conjunction with doxorubicin a small number of cases of secondary acute myeloid leukemia occurred within two years of treatment initiation. Urinary bladder malignancies generally have occurred in patients who previously had hemorrhagic cystitis. In patients treated with cyclophosphamide-containing regimens for a variety of solid tumors, isolated case reports of secondary malignancies have been published. One case of carcinoma of the renal pelvis was reported in a patient receiving long-term cyclophosphamide therapy for cerebral vasculitis. The possibility of cyclophosphamide-induced malignancy should be considered in any benefit-to-risk assessment for use of the drug. Cyclophosphamide can cause fetal harm when administered to a pregnant woman and such abnormalities have been reported following cyclophosphamide therapy in pregnant women. Abnormalities were found in two infants and a six-month-old fetus born to women treated with cyclophosphamide. Ectrodactylia was found in two of the three cases. Normal infants have also been born to women treated with cyclophosphamide during pregnancy, including the first trimester. If this drug is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes. Development of sterility appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment. Cyclophosphamide-induced sterility may be irreversible in some patients. Amenorrhea associated with decreased estrogen and increased gonadotropin secretion develops in a significant proportion of women treated with cyclophosphamide. Affected patients generally resume regular menses within a few months after cessation of therapy. Girls treated with cyclophosphamide during prepubescence generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged cyclophosphamide treatment in late prepubescence has been reported. Girls treated with cyclophosphamide during prepubescence subsequently have conceived. Men treated with cyclophosphamide may develop oligospermia or azoospermia associated with increased gonadotropin but normal testosterone secretion. Sexual potency and libido are unimpaired in these patients. Boys treated with cyclophosphamide during prepubescence develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion. Some degree of testicular atrophy may occur. Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy. Men temporarily rendered sterile by cyclophosphamide have subsequently fathered normal children. Urinary System Hemorrhagic cystitis may develop in patients treated with cyclophosphamide. Rarely, this condition can be severe and even fatal. Fibrosis of the urinary bladder, sometimes extensive, also may develop with or without accompanying cystitis. Atypical urinary bladder epithelial cells may appear in the urine. These adverse effects appear to depend on the dose of cyclophosphamide and the duration of therapy. Such bladder injury is thought to be due to cyclophosphamide metabolites excreted in the urine. Forced fluid intake helps to assure an ample output of urine, necessitates frequent voiding, and reduces the time the drug remains in the bladder. This helps to prevent cystitis. Hematuria usually resolves in a few days after cyclophosphamide treatment is stopped, but it may persist. Medical and/or surgical supportive treatment may be required, rarely, to treat protracted cases of severe hemorrhagic cystitis. It is usually necessary to discontinue cyclophosphamide therapy in instances of severe hemorrhagic cystitis. Cardiac Toxicity Although a few instances of cardiac dysfunction have been reported following use of recommended doses of cyclophosphamide, no causal relationship has been established. Acute cardiac toxicity has been reported with doses as low as 2.4 g/m2 to as high as 26 g/m2, usually as a portion of an intensive antineoplastic multi-drug regimen or in conjunction with transplantation procedures. In a few instances with high doses of cyclophosphamide, severe, and sometimes fatal, congestive heart failure has occurred after the first cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis. Pericarditis has been reported independent of any hemopericardium. No residual cardiac abnormalities, as evidenced by electrocardiogram or echocardiogram appear to be present in patients surviving episodes of apparent cardiac toxicity associated with high doses of cyclophosphamide. Cyclophosphamide has been reported to potentiate doxorubicin-induced cardiotoxicity. Infections Treatment with cyclophosphamide may cause significant suppression of immune responses. Serious, sometimes fatal, infections may develop in severely immunosuppressed patients. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop viral, bacterial, fungal, protozoan, or helminthic infections. Other Anaphylactic reactions have been reported; death has also been reported in association with this event. Possible cross-sensitivity with other alkylating agents has been reported. Precautions General Special attention to the possible development of toxicity should be exercised in patients being treated with cyclophosphamide if any of the following conditions are present. Leukopenia Thrombocytopenia Tumor cell infiltration of bone marrow Previous X-ray therapy Previous therapy with other cytotoxic agents Impaired hepatic function Impaired renal function Laboratory Tests During treatment, the patient’s hematologic profile (particularly neutrophils and platelets) should be monitored regularly to determine the degree of hematopoietic suppression. Urine should also be examined regularly for red cells which may precede hemorrhagic cystitis. Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted. Adrenalectomy Since cyclophosphamide has been reported to be more toxic in adrenalectomized dogs, adjustment of the doses of both replacement steroids and cyclophosphamide may be necessary for the adrenalectomized patient. Wound Healing Cyclophosphamide may interfere with normal wound healing. Carcinogenesis, Mutagenesis, and Impairment of Fertility See WARNINGS for information on carcinogenesis, mutagenesis, and impairment of fertility. Pregnancy Pregnancy Category D—See WARNINGS. Nursing Mothers Cyclophosphamide is excreted in breast milk. Because of the potential for serious adverse reactions and the potential for tumorigenicity shown for cyclophosphamide in humans, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use The safety profile of Cytoxan in pediatric patients is similar to that of the adult population (see ADVERSE REACTIONS). Geriatric Use Insufficient data from clinical studies of Cytoxan for malignant lymphoma, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, retinoblastoma, and breast carcinoma are available for patients 65 years of age and older to determine whether they respond differently than younger patients. In two clinical trials in which cyclophosphamide was compared with paclitaxel, each in combination with cisplatin, for the treatment of advanced ovarian carcinoma, 154 (28%) of 552 patients who received cyclophosphamide plus cisplatin were 65 years or older. Subset analyses (<65 versus >65 years) from these trials, published reports of clinical trials of cyclophosphamide-containing regimens in breast cancer and non-Hodgkin’s lymphoma, and postmarketing experience suggest that elderly patients may be more susceptible to cyclophosphamide toxicities. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range and adjusting as necessary based on patient response (see DOSAGE AND ADMINISTRATION: Treatment of Malignant Diseases). Adverse Reactions Information on adverse reactions associated with the use of Cytoxan (cyclophosphamide) is arranged according to body system affected or type of reaction. The adverse reactions are listed in order of decreasing incidence. The most serious adverse reactions are described in the WARNINGS section. Reproductive System See WARNINGS for information on impairment of fertility. Digestive System Nausea and vomiting commonly occur with cyclophosphamide therapy. Anorexia and, less frequently, abdominal discomfort or pain and diarrhea may occur. There are isolated reports of hemorrhagic colitis, oral mucosal ulceration and jaundice occurring during therapy. These adverse drug effects generally remit when cyclophosphamide treatment is stopped. Skin and Its Structures Alopecia occurs commonly in patients treated with cyclophosphamide. The hair can be expected to grow back after treatment with the drug or even during continued drug treatment, though it may be different in texture or color. Skin rash occurs occasionally in patients receiving the drug. Pigmentation of the skin and changes in nails can occur. Very rare reports of Stevens-Johnson syndrome and toxic epidermal necrolysis have been received during postmarketing surveillance; due to the nature of spontaneous adverse event reporting, a definitive causal relationship to cyclophosphamide has not been established. Hematopoietic System Leukopenia occurs in patients treated with cyclophosphamide, is related to the dose of drug, and can be used as a dosage guide. Leukopenia of less than 2000 cells/mm3 develops commonly in patients treated with an initial loading dose of the drug, and less frequently in patients maintained on smaller doses. The degree of neutropenia is particularly important because it correlates with a reduction in resistance to infections. Fever without documented infection has been reported in neutropenic patients. Thrombocytopenia or anemia develop occasionally in patients treated with Cytoxan. These hematologic effects usually can be reversed by reducing the drug dose or by interrupting treatment. Recovery from leukopenia usually begins in 7 to 10 days after cessation of therapy. Urinary System See WARNINGS for information on cystitis and urinary bladder fibrosis. Hemorrhagic ureteritis and renal tubular necrosis have been reported to occur in patients treated with cyclophosphamide. Such lesions usually resolve following cessation of therapy. Infections See WARNINGS for information on reduced host resistance to infections. Carcinogenesis See WARNINGS for information on carcinogenesis. Respiratory System Interstitial pneumonitis has been reported as part of the postmarketing experience. Interstitial pulmonary fibrosis has been reported in patients receiving high doses of cyclophosphamide over a prolonged period. Other Anaphylactic reactions have been reported; death has also been reported in association with this event. Possible cross-sensitivity with other alkylating agents has been reported. SIADH (syndrome of inappropriate ADH secretion) has been reported with the use of cyclophosphamide. Malaise and asthenia have been reported as part of the postmarketing experience. Overdosage No specific antidote for cyclophosphamide is known. Overdosage should be managed with supportive measures, including appropriate treatment for any concurrent infection, myelosuppression, or cardiac toxicity should it occur. Cytoxan Dosage and Administration Treatment of Malignant Diseases Adults and Children When used as the only oncolytic drug therapy, the initial course of Cytoxan for patients with no hematologic deficiency usually consists of 40 to 50 mg/kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 to 15 mg/kg given every 7 to 10 days or 3 to 5 mg/kg twice weekly. Oral Cytoxan dosing is usually in the range of 1 to 5 mg/kg/day for both initial and maintenance dosing. Many other regimens of intravenous and oral Cytoxan have been reported. Dosages must be adjusted in accord with evidence of antitumor activity and/or leukopenia. The total leukocyte count is a good, objective guide for regulating dosage. Transient decreases in the total white blood cell count to 2000 cells/mm3 (following short courses) or more persistent reduction to 3000 cells/mm3 (with continuing therapy) are tolerated without serious risk of infection if there is no marked granulocytopenia. When Cytoxan is included in combined cytotoxic regimens, it may be necessary to reduce the dose of Cytoxan as well as that of the other drugs. Cytoxan and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system being used. Patients with compromised renal function may show some measurable changes in pharmacokinetic parameters of Cytoxan metabolism, but there is no consistent evidence indicating a need for Cytoxan dosage modification in patients with renal function impairment. Treatment of Nonmalignant Diseases Biopsy Proven “Minimal Change’’ Nephrotic Syndrome in Children An oral dose of 2.5 to 3 mg/kg daily for a period of 60 to 90 days is recommended. In males, the incidence of oligospermia and azoospermia increases if the duration of Cytoxan treatment exceeds 60 days. Treatment beyond 90 days increases the probability of sterility. Adrenocorticosteroid therapy may be tapered and discontinued during the course of Cytoxan therapy. See PRECAUTIONS concerning hematologic monitoring. Preparation and Handling of Solutions Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Add the diluent to the vial and shake it vigorously to dissolve. If the powder fails to dissolve immediately and completely, it is advisable to allow the vial to stand for a few minutes. Use the quantity of diluent shown below to constitute the product: Dosage Strength Cytoxan Contains Cyclophosphamide Monohydrate Quantity of Diluent 500 mg 534.5 mg 25 mL 1 g 1069.0 mg 50 mL 2 g 2138.0 mg 100 mL For Direct Injection Cytoxan should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of Cytoxan may be injected intravenously, intramuscularly, intraperitoneally, or intrapleurally if constituted by adding 0.9% sterile sodium chloride solution. For Infusion Cytoxan may be prepared for parenteral use by infusion using any of the following methods: Cytoxan constituted with 0.9% sterile sodium chloride may be infused without further dilution. Cytoxan constituted with 0.9% sterile sodium chloride may be infused following further dilution in the following: Dextrose Injection, USP (5% dextrose) Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride) 5% Dextrose and Ringer’s Injection Lactated Ringer’s Injection, USP Sodium Chloride Injection, USP (0.45% sterile sodium chloride) Sodium Lactate Injection, USP (1/6 molar sodium lactate) Cytoxan sterile powder may be prepared for parenteral use by infusion by adding Sterile Water for Injection, USP. Cytoxan, constituted in water, is hypotonic and should not be injected directly. Prior to infusion, solutions of sterile powder constituted in Sterile Water for Injection, USP must be further diluted in one of the following: Dextrose Injection, USP (5% dextrose) Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride) 5% Dextrose and Ringer’s Injection Lactated Ringer’s Injection, USP Sodium Chloride Injection, USP (0.45% sterile sodium chloride) Sodium Lactate Injection, USP (1/6 molar sodium lactate) Stability of Constituted Parenteral Solutions Cytoxan (prepared for either direct injection or infusion) is chemically and physically stable for 24 hours at room temperature or for six days in the refrigerator; it does not contain any antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions. The osmolarities of solutions of Cytoxan constituted with water and 0.9% sterile sodium chloride solution are found in the following table: Cytoxan and Diluent mOsm/L 5 mL water per 100 mg cyclophosphamide (anhydrous) 74 5 mL 0.9% sterile sodium chloride solution per 100 mg cyclophosphamide (anhydrous) 374 Isotonic 0.9% sterile sodium chloride solution has an osmolarity of 289 mOsm/L. For Oral Administration Extemporaneous liquid preparations of Cytoxan for oral administration may be prepared by dissolving Cytoxan in Aromatic Elixir, N.F. Such preparations should be stored under refrigeration in glass containers and used within 14 days. How is Cytoxan Supplied Cytoxan® contains cyclophosphamide monohydrate and is supplied in vials for single dose use. Cytoxan (cyclophosphamide for injection, USP). NDC 0015-0502-41 500 mg vial, carton of 1 NDC 0015-0505-41 1.0 g vial, carton of 1 NDC 0015-0506-41 2.0 g vial, carton of 1 Store vials at or below 77° F (25° C). During transport or storage of Cytoxan vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide. Vials containing melted substance can be visually differentiated. Melted cyclophosphamide is a clear or yellowish viscous liquid usually found as a connected phase or in droplets in the affected vials. Do not use Cytoxan vials if there are signs of melting. Cytoxan® Tablets, 25 mg and Cytoxan Tablets, 50 mg, are white tablets with blue flecks containing 25 mg and 50 mg cyclophosphamide (anhydrous), respectively. Cytoxan Tablets (cyclophosphamide tablets, USP). NDC 0015-0503-01 50 mg, bottles of 100 NDC 0015-0504-01 25 mg, bottles of 100 Store tablets at or below 77° F (25° C); tablets will withstand brief exposure to temperatures up to 86° F (30° C) but should be protected from temperatures above 86° F (30° C). Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. To minimize the risk of dermal exposure, always wear impervious gloves when handling vials containing Cytoxan sterile powder for injection, or bottles containing Cytoxan tablets. This includes all handling activities in clinical settings, pharmacies, storerooms, and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration. 附件: 2010111117555539.pdf --------------------------------------------------------------- 注：以下产品不同规格和不同价格，购买时请电话咨询为准！ --------------------------------------------------------------- 产地国家: 美国 原产地英文商品名: CYTOXAN 1g/12mls/vial 原产地英文药品名: CYCLOPHOSPHAMIDE 中文参考商品译名: CYTOXAN 1克/12毫升/瓶 中文参考药品译名: 环磷酰胺 中文参考化合物名称: 对-［双-(β-氯乙基)胺基］-β-苯丙氨酸 生产厂家中文参考译名: 百特 生产厂家英文名: BAXTER HLTHCARE --------------------------------------------------------------- 产地国家: 美国 原产地英文商品名: CYTOXAN 2g/12mls/vial 原产地英文药品名: CYCLOPHOSPHAMIDE 中文参考商品译名: CYTOXAN 2克/12毫升/瓶 中文参考药品译名: 环磷酰胺 中文参考化合物名称: 对-［双-(β-氯乙基)胺基］-β-苯丙氨酸 生产厂家中文参考译名: 百特 生产厂家英文名: BAXTER HLTHCARE